Table 2.
Sample Characteristics by Exposure Pattern
| Singular/ Pain |
Singular/ Comorbid |
Singular/ Both |
Episodic/ Pain |
Episodic/ Both |
Switching/ Both |
Sustained/ Both |
Multiplex/ Both |
Total | |
|---|---|---|---|---|---|---|---|---|---|
| N | 2 | 4 | 3 | 3 | 10 | 3 | 2 | 3 | 30 |
| Age (years) | |||||||||
| Mean (SD) | 57.5 (4.9) | 52.8 (12.8) | 47 (12.1) | 47 (3.6) | 51 (11.9) | 49.3 (4.7) | 58.5 (9.2) | 48.3 (16.3) | 50.9 (10.4) |
| Range | 54–61 | 34–62 | 40–61 | 44–51 | 23–62 | 44–53 | 52–65 | 30–61 | 23–65 |
| Sex n (%) | |||||||||
| Male | 2 (100) | 4 (100) | 1 (33.3) | 1 (33.3) | 1 (10) | 1 (33.3) | 2 (100) | 2 (66.7) | 14 (46.7) |
| Female | --- | --- | 2 (66.7) | 2 (66.7) | 9 (90) | 2 (66.7) | --- | 1 (33.3) | 16 (53.3) |
| Race n (%) | |||||||||
| White | 2 (100) | 2 (50) | 3 (100) | 1 (33.3) | 6 (60) | --- | 2 (100) | 2 (66.7) | 18 (60) |
| Black | --- | 2 (50) | --- | 2 (66.7) | 4 (40) | 2 (66.7) | --- | 1 (33.3) | 11 (36.7) |
| Biracial | --- | --- | --- | --- | --- | 1 (33.3) | --- | --- | 1 (3.3) |
| Ethnicity n (%) | |||||||||
| Not Hispanic | 2 (100) | 3 (75) | 3 (100) | 2 (66.7) | 9 (90) | 2 (66.7) | 2 (100) | 3 (100) | 26 (86.7) |
| Hispanic | --- | --- | --- | --- | --- | 1 (33.3) | --- | --- | 1 (3.3) |
| Unknown | --- | 1 (25) | --- | 1 (33.3) | 1 (10) | --- | --- | --- | 3 (10) |
| PGxA Opioid n (%) | |||||||||
| Tramadol | 2 (100) | 3 (75) | 2 (66.7) | 3 (100) | 8 (80) | 2 (66.7) | 2 (100) | 2 (66.7) | 24 (80) |
| Codeine | --- | 1 (25) | 1 (33.3) | --- | 2 (20) | 1 (33.3) | --- | 1 (33.3) | 6 (20) |
| CYP2D6 Drug Metabolizing Phenotype | |||||||||
| UM | --- | --- | --- | 1 (33.3) | --- | --- | --- | 1 (33.3) | 2 (6.7) |
| NM | 1 (50) | 4 (100) | 3 (100) | 2 (66.7) | 8 (80) | 3 (100) | 2 (100) | 2 (66.7) | 25 (83.3) |
| IM | 1 (50) | --- | --- | --- | --- | --- | --- | --- | 1 (3.3) |
| PM | --- | --- | --- | --- | 2 (20) | --- | --- | --- | 2 (6.7) |
| Potential cytochrome P450 DDGI | |||||||||
| n (%)1 | --- | --- | 1 (25) | 1 (33.3) | 2 (20) | 2 (66.7) | 1 (50) | --- | 7 (23.3) |
SD = standard deviation; PGxA = Pharmacogenetically Actionable; UM = Ultra-rapid Metabolizer (CYP2D6 activity score: >2); NM = Normal Metabolizer (CYP2D6 activity score: 1–2); IM = Intermediate Metabolizer (CYP2D6 activity score: 0.5); PM = Poor Metabolizer (CYP2D6 activity score: 0); DDGI = drug-drug-gene interaction
1
Number and percentage of patients with at least 1 potential DDGI identified.